Johan Hedin is appointed new Chairman of ChromoGenics

Report this content

Johan Hedin appointed new Chairman of the Board of ChromoGenics AB (publ).

Chairman of the Board Christer Simrén will hand over the Chairman's assignment to Johan Hedin.

Chairman of the Board Christer Simrén says; “ChromoGenics is with its unique products in a growth phase. During the spring I have taken up the position as CEO of CellMark, which means that my situation no longer allows a dynamic Chairman assignment in a listed company such as ChromoGenics. I am very pleased to have participated in the company's development to a promising commercial expansion. It is a pleasure to hand over to Johan Hedin who has solid industrial experience and business acumen.

Johan Hedin has long and broad industrial experience, primarily in the forest industry, most recently as Sales and Marketing Director at Holmen.

“I am honored to take over as Chairman of the exciting phase that ChromoGenics is in. In times of great focus on sustainable, energy-efficient solutions, the company's product offering is in the lead. “I look forward to working with ChromoGenic's board and management to take the next step in ChromoGenic's growth journey”.


Jerker Lundgren, CEO
Lars Ericsson, CFO and Head of Communications
Tel: +46 (0)18 430 0430
Certified Adviser: G&W Fondkommission, e-mail:, tel.: +46 (0) 8 503 000 50

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

About ChromoGenics
ChromoGenics offers dynamic glass with controllable heat- and light transmission and static glass with world leading performance. The company’s unique technology ConverLight® provides sustainable solar control for increased indoor comfort and energy efficiency. ConverLight also contributes to Green Building certifications. In 2016 the company started commercial sales to real estate projects in Scandinavia.

ChromoGenics is located in Uppsala, Sweden, and the technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.





Documents & Links